Introduction {#Sec1}
============

Pharmacokinetic (PK) of drugs in critically ill patients could vary from the general population. Patients undergoing hemodiafiltration (HDF) could present lower linezolid (LZ) concentration than expected. The pharmacokinetic/pharmacodynamic analysis (PK/ PD) is a useful tool to optimize dosing regimens of antibiotic therapy.

Objectives {#Sec2}
==========

To evaluate the efficacy and safety of LZ for the treatment of infections caused by gram-positive microorganisms (GPM) in the Intensive Care Unit (ICU) patients undergoing HDF using a PK/PD analysis and Monte Carlo simulation (MCS).

Methods {#Sec3}
=======

Study developed in three tertiary hospitals in patients with severe sepsis, HDF and treatment with LZ (600mg q12h). 8 each patient blood (prefilter and postfilter) and ultrafiltrate samples were taken. Concentrations of linezolid were determined by HPLC-UV. PK analysis and MCS were performed using Phoenix WinNonlin Version 6.3 (Pharsight) and Oracle Crystal Ball programs to assess the probability of successful treatment (PST) \[area under the curve (AUC24)/MIC\> 100 for different MICs\], the probability of C~min~\>2 mg/L and the risk of overexposure (RO) \[C~min~\> 10 mg /L and/or AUC24\> 400 mg \* h/L\] at doses of 600mg q12 and q8h. Patients were grouped by liver and renal function considering impaired liver function (ILF) the elevation\> 2 times transaminase and/or elevated bilirubin and severe renal dysfunction (SRD) the presence of CrCl \< 15 ml/min. Group (G) 0: both normal, G1: ILF or SRD, G2: both. Quantitative variables were expressed as mean and standard deviation (SD), qualitative as percentages. α significance level of 0,05.

Results {#Sec4}
=======

26 patients were included. The AUC 24 (mg \* h / L) was: G0 111 (SD 39), G1 155 (SD 79) and G2 246 (SD64), the C~min~ (mg/L) was: G0 1,5 (SD 1,2), G1 2,5 (SD 1,8) and G2 4,6 (SD 2) and the clearance (Cl) (L/h) was: G0 12 (SD 4), G1 10,1 (SD 5,9) and G2 8,9 (SD 5,1). The PST was 96, 81, 38 and 0% for GPM with MICs of 0,5, 1, 2 and 4 mg/L. In the MCS, 600 mg 12qh ensures PST\> 80% for MIC ≤1mg/L in the presence of some dysfunction (G1 and G2), increasing to\> 90% for all groups with 600 mg q8h without RO. In the G2, the current dose assures PST\> 70% for MIC of 2, increasing to \>90% with 600mg q8h but with high RO (\> 30%). No amount is effective for MIC ≥4 mg/L. The probability of C~min~ \>2 mg/L was 23, 33 and 85% for G0, G1 and G2 respectively, increasing to 60% in G0 and G1 with 600 mg q8h (see summary table in Figure [1](#Fig1){ref-type="fig"}).Figure 1

Conclusions {#Sec5}
===========

In patients with RRT, 600 mg q12h guarantees PST \>80% for MIC ≤1 in the presence of SRD and/or ILF. For this MIC, 600 mg q8h guarantees high PST in all patients and increases the probability of Cmin\> 2. For MGP with MIC of 2, only in the presence of both dysfunctions is possible achieving the PK/PD target.
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